Vertex Pharmaceuticals Incorporated Chugs Along
Vertex Pharmaceuticals (NASDAQ: VRTX) keeps chugging along, generating increased sales for its two cystic fibrosis drugs as it gains additional approvals to treat more patients, and producing clinical trial data for its drug candidates that will hopefully be generating sales in the coming years.
Metric
Q2 2017
Source: Fool.com
Vertex Pharmaceuticals Inc. Stock
€430.20
-0.190%
With 57 Buy predictions and 2 Sell predictions Vertex Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 440 € shows a slightly positive potential of 2.28% compared to the current price of 430.2 € for Vertex Pharmaceuticals Inc..
